Schizoaffective Disorder Market Report 2026

Schizoaffective Disorder Market Overview

• Schizoaffective Disorder market size has reached to $7.74 billion in 2025 • Expected to grow to $9.83 billion in 2030 at a compound annual growth rate (CAGR) of 4.8% • Growth Driver: Impact Of Rising Neurological Disorders On Mental Health • Market Trend: Innovative Drug Development For Improved Mental Health Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Schizoaffective Disorder Market?

Schizoaffective disorder is a mental illness characterized by a blend of schizophrenia symptoms, including delusions or hallucinations, and mood disorder symptoms, such as depressive or manic episodes. This condition is long-term and necessitates a multidisciplinary approach to treatment, incorporating both therapeutic and pharmaceutical interventions to address its multifaceted nature. The main drugs in the schizoaffective disorder are antipsychotic medication, mood stabilizers, antidepressant medication, and anticonvulsants. Antipsychotic medications are utilized to control symptoms of psychosis, such as hallucinations, delusions, and disorganized thinking. Various causes involve genetic factors, environmental factors, and chemical factors. These treatments can be administered in hospitals, clinics, and other end users.

What Is The Schizoaffective Disorder Market Growth Forecast?

The schizoaffective disorder market size is expected to see steady growth in the next few years. It will grow to $9.83 billion in 2030 at a compound annual growth rate (CAGR) of 4.8%. The growth in the forecast period can be attributed to development of novel atypical antipsychotics, increasing demand for long-acting formulations, rising healthcare spending on mental health, expansion of community-based mental health programs, growing focus on personalized treatment approaches. Major trends in the forecast period include increasing use of combination therapy with antipsychotics and mood stabilizers, rising adoption of long-acting injectable antipsychotics, growing emphasis on early diagnosis and intervention, increasing incorporation of psychotherapy alongside pharmacological treatment, expanding use of digital mental health support tools.

Global Schizoaffective Disorder Market Segmentation

1) By Drugs: Antipsychotic Medication, Mood Stabilizers, Antidepressant Medication, Anticonvulsants 2) By Causes: Genetic Factors, Environmental Factors, Chemical Factors 3) By End User: Hospitals, Clinics, Other End User Subsegments: 1) By Antipsychotic Medication: Atypical Antipsychotics, Typical Antipsychotics 2) By Mood Stabilizers: Lithium, Valproate, Lamotrigine, Carbamazepine 3) By Antidepressant Medication: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs) 4) By Anticonvulsants: Lamotrigine, Valproate, Topiramate, Levetiracetam

What Is The Driver Of The Schizoaffective Disorder Market?

The rise in neurological disorders is expected to drive the growth of the schizoaffective disorder market going forward. Neurological disorders are medical conditions that affect the nervous system, including the brain, spinal cord, and nerves, leading to various cognitive, motor, and sensory dysfunctions. The rise in neurological disorders is attributed to factors such as genetic mutations, infections, traumatic injuries, environmental toxins, autoimmune responses, or degenerative processes affecting the nervous system. The prevalence of neurological disorders contributes to the increased detection and occurrence of schizoaffective disorder through shared biological mechanisms, improved diagnostic capabilities, and growing awareness. For instance, in April 2023, the National Library of Medicine, a US-based medical library for medical research information, reported that around 6.7 million Americans are affected by Alzheimer's in 2023, and this number is expected to grow to 13.8 million by 2060. Therefore, the rise in neurological disorders is driving the schizoaffective disorder industry.

Key Players In The Global Schizoaffective Disorder Market

Major companies operating in the schizoaffective disorder market are Pfizer Inc., Johnson & Johnson, Bristol Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Zydus Lifesciences Limited, Neurocrine Biosciences Inc., Alkermes Inc., Luye Pharma Group Ltd., Merz Pharma GmbH & Co. KGaA, Acadia Pharmaceuticals Inc., Intra-Cellular Therapies Inc., Cerevel Therapeutics Inc., Avanir Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., Reviva Pharmaceuticals Inc., Zogenix Inc., Sunovion Pharmaceuticals Inc., Newron Pharmaceuticals S.p.A., Sage Therapeutics Inc., Lyndra Therapeutics Inc., BioXcel Therapeutics Inc.

Global Schizoaffective Disorder Market Trends and Insights

Major companies operating in the schizoaffective disorder market are focusing on developing innovative drugs, such as extended-release injectable suspension drugs, to enhance treatment efficacy, improve patient compliance, and reduce dosing frequency. An extended-release injectable suspension drug is a type of injectable medication designed to release its active ingredient slowly over an extended period. This formulation allows for less frequent dosing than traditional immediate-release formulations, improving patient convenience and adherence to treatment. For instance, in July 2024, Luye Pharma Group Ltd., a China-based pharmaceutical company, announced that the US Food and Drug Administration (FDA) has approved ERZOFRI (paliperidone palmitate) extended-release injectable suspension for the treatment of schizophrenia and schizoaffective disorder. This innovative treatment offers a long-acting injectable formulation designed to deliver therapeutic effects over an extended period, reducing the frequency of administration for patients. The extended-release technology ensures consistent medication levels in the body, improving patient adherence and reducing the risk of relapse. The convenience of fewer injections compared to oral medications can significantly enhance the quality of life for patients with chronic mental health conditions.

What Are Latest Mergers And Acquisitions In The Schizoaffective Disorder Market?

In March 2024, Bristol Myers Squibb, a US-based biopharmaceutical company, acquired Karuna Therapeutics Inc. for an undisclosed amount. With this acquisition, Bristol Myers Squibb aims to strengthen its neuroscience portfolio by adding Karuna Therapeutics' innovative schizophrenia treatment, KarXT, and its early-stage pipeline. Karuna Therapeutics Inc. is a US-based biopharmaceutical company that specializes in developing treatments for psychiatric and neurological conditions, including schizophrenia.

Regional Outlook

North America was the largest region in the schizoaffective disorder market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Schizoaffective Disorder Market?

The schizoaffective disorder market consists of revenues earned by entities by providing services such as clinical interviews, psychological assessments, cognitive-behavioral therapy (CBT), interpersonal therapy, and vocational rehabilitation. The market value includes the value of related goods sold by the service provider or included within the service offering. The schizoaffective disorder market includes sales of drugs such as risperidone, olanzapine, lithium and valproate, and fluoxetine or sertraline. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Schizoaffective Disorder Market Report 2026?

The schizoaffective disorder market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the schizoaffective disorder industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.